title: Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
abstract: Over 90% of leukemic blasts in patients with acute lymphoblastic leukemia express the marker CD22. Inotuzumab ozogamicin (INO) is a CD22-directed humanized monoclonal antibody conjugated to the potent cytotoxin, calicheamicin, via an acid labile linker. INO has shown high rates of response in the treatment of relapsed and refractory (R/R) ALL in single-agent studies, with fewer adverse effects than traditional cytotoxic chemotherapy. Given this experience, studies are now being done to evaluate INO in combination with low-intensity chemotherapy as frontline treatment for older adults with ALL and patients with R/R disease. Herein we will discuss the use of INO in the treatment of acute lymphoblastic leukemia.
authors.affiliation: a Department of Leukemia , U.T. M.D. Anderson Cancer Center , Houston , TX , USA.
authors.forename: Jenny
authors.initials: J
authors.lastname: Dahl
authors.affiliation: a Department of Leukemia , U.T. M.D. Anderson Cancer Center , Houston , TX , USA.
authors.forename: Kayleigh
authors.initials: K
authors.lastname: Marx
authors.affiliation: a Department of Leukemia , U.T. M.D. Anderson Cancer Center , Houston , TX , USA.
authors.forename: Elias
authors.initials: E
authors.lastname: Jabbour
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006207:Half-Life; D006801:Humans; D018796:Immunoconjugates / Q000493:pharmacokinetics / Q000627:therapeutic use; D000080045:Inotuzumab Ozogamicin; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C497867:CD22 protein, human; D018796:Immunoconjugates; D051918:Sialic Acid Binding Ig-like Lectin 2; D000080045:Inotuzumab Ozogamicin
keywords: CD22; Inotuzumab; acute lymphoblastic leukemia; refractory; relapsed